- Home
- OPFI vs AMRN Comparison
OPFI vs AMRN Comparison
Compare OPFI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$14.36
Company Overview
Basic Information| Metric | OPFI | AMRN |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | OPFI | AMRN |
|---|---|---|
| Price | $11.16 | $14.36 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $11.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 558.3K | 83.6K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $335,423,000.00 | $226,733,000.00 |
| Revenue This Year | $120.32 | N/A |
| Revenue Next Year | $10.85 | N/A |
| P/E Ratio | $80.84 | ★ N/A |
| Revenue Growth | ★ 28.69 | N/A |
| 52 Week Low | $6.65 | $7.08 |
| 52 Week High | $17.73 | $20.90 |
Technical Indicators
Market Signals| Indicator | OPFI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 35.29 |
| Support Level | $10.03 | $13.64 |
| Resistance Level | $10.36 | $14.67 |
| Average True Range (ATR) | 0.35 | 0.74 |
| MACD | 0.19 | -0.15 |
| Stochastic Oscillator | 91.86 | 24.21 |
Price Performance
Historical Comparison OPFI
AMRN
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.